Biomea Fusion

Biomea Fusion’s lead candidate icovamenib (BMF‑219), a covalent menin inhibitor, has shown statistically significant and clinically meaningful reductions in HbA1c at Week 26 in type 2 diabetes patients. The drug was generally well tolerated with a favorable safety profile. However, the FDA placed a full clinical hold on ongoing trials due to potential hepatotoxicity observed at higher doses; most adverse events were mild to moderate. The company plans further engagement with the FDA based on promising efficacy data and aims to resume studies after addressing safety concerns. Oncology programs are being deprioritized as the company pivots toward metabolic diseases.